Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

http://www.natap.org/2003/sept/093003_10.htm

This is the study of 3,000 patients receiving one of 10 IFN based regimens assessing impact of PEG-IFN/RBV in fibrosis and activity in responders and nonresponders, and cirrhotics.

The findings are interesting and were reported in Gastroenterology. This report contains tables and charts from the published study.